card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Through a CRO's Perspective: Innovative, Agile Solutions In Vaccine Efficacy Testing

Vaccine eBook
Home / Insights / Through a CRO's Perspective: Innovative, Agile Solutions In Vaccine Efficacy Testing

The outbreak of the SARS-CoV-2 virus caused a sudden shift in focus for the pharmaceutical industry. After the genetic sequence of the virus was released in early 2020, manufacturers across the globe began the race to research and develop vaccines to combat the virus. In order to avoid the development delays that would occur due to a limited number of qualified BSL-3 facilities, IQVIA Laboratories pivoted their approach to solve the problem before it could even start. Learn more about our efforts to combat COVID-19 in our new eBook.

Complete the form to access this vaccine eBook